Afficher la notice abrégée

Inclusion of elderly or frail patients in randomized controlled trials of targeted therapies for the treatment of metastatic colorectal cancer: A systematic review

dc.rights.licenseopenen_US
dc.contributor.authorGOUVERNEUR, Amandine
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorSALVO, Francesco
dc.contributor.authorBERDAI, Driss
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorMOORE, Nicholas
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorFOURRIER-REGLAT, Annie
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorNOIZE, Pernelle
dc.date.accessioned2020-11-10T14:35:17Z
dc.date.available2020-11-10T14:35:17Z
dc.date.issued2018-01
dc.identifier.issn1879-4068en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/12214
dc.description.abstractEnTreatment of metastatic colorectal cancer (mCRC) has been modified since the launching of targeted therapies. Colorectal cancer (CRC) is common in elderly patients; their representation in randomized controlled trials (RCTs) is thus crucial. This study aimed to evaluate and quantify the inclusion of elderly/frail patients in RCTs of targeted therapies in mCRC. A systematic review using Medline, Scopus, Cochrane Database and ISI Web of Science was performed to identify all phase II/III RCTs of bevacizumab, cetuximab, panitumumab, regorafenib and aflibercept in mCRC until January 2015. Two reviewers independently performed studies selection, and data extraction. The protocol was registered in Prospero (CRD42015016163). Among 1,369, identified publications, 54 RCTs were selected. Nine RCTs (17%) excluded elderly patients; median age of the included population was <65years old in 50 RCTs (93%). Twenty RCTs (37%) excluded frail patients, and many RCTs excluded patients with uncontrolled hypertension or heart failure, patients treated with specific drugs (mainly anticoagulants), and patients with inadequate creatinine clearance. Elderly/frail patients are underrepresented in RCTs studying targeted therapies in mCRC, and those elderly patients included in RCTs do not reflect well the general elderly population with mCRC because of the exclusion criteria. RCTs results concerning targeted therapies can be inferred only to relatively healthy elderly subjects.
dc.language.isoENen_US
dc.subject.enPharmacoEpi-Drugs
dc.subject.enCIC1401
dc.title.enInclusion of elderly or frail patients in randomized controlled trials of targeted therapies for the treatment of metastatic colorectal cancer: A systematic review
dc.title.alternativeJ Geriatr Oncolen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1016/j.jgo.2017.08.001en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed28844343en_US
bordeaux.journalJournal of geriatric oncologyen_US
bordeaux.page15-23en_US
bordeaux.volume9en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - U1219en_US
bordeaux.issue1en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.teamPharmacoEpi-Drugsen_US
bordeaux.teamCIC1401en_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-02998597
hal.version1
hal.date.transferred2020-11-10T14:35:22Z
hal.exporttrue
bordeaux.COinSctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft.jtitle=Journal%20of%20geriatric%20oncology&amp;rft.date=2018-01&amp;rft.volume=9&amp;rft.issue=1&amp;rft.spage=15-23&amp;rft.epage=15-23&amp;rft.eissn=1879-4068&amp;rft.issn=1879-4068&amp;rft.au=GOUVERNEUR,%20Amandine&amp;SALVO,%20Francesco&amp;BERDAI,%20Driss&amp;MOORE,%20Nicholas&amp;FOURRIER-REGLAT,%20Annie&amp;rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée